Abstract:Mutations in isocitrate dehydrogenase (IDH) are frequently found in low-grade gliomas, secondary glioblastoma, chondrosarcoma, acute myeloid leukemias, and intrahepatic cholangiocarcinoma. However, the molecular mechanisms of how IDH2 mutations induce carcinogenesis remain unclear. Using overlapping PCR, transfection, immunoblotting, immunoprecipitation, measurements of enzyme activity, glucose, lactic acid, ATP, and reactive oxygen species (ROS), cell viability, protein degradation assays post-inhibition of the 26S proteasome (bortezomib) or HSP90 (17-AAG), and a homology model, we demonstrated that the properties of ten cancer-associated IDH2 variants (R140G/Q/W and R172S/K/M/W/G/C/P) arising from point mutations are closely related to their structure and stability. Compared with wild-type IDH2, the R172 and R140 point mutations resulted in a decrease in IDH2 activity, ROS, and lactate levels and an increase in glucose and ATP levels under normal and hypoxic conditions, indicating that mutant IDH2 increases cell dependency on mitochondrial oxidative phosphorylation, and reduces glycolysis under hypoxia. Overexpression of most of IDH2 point mutants showed anti-proliferative effects in the 293T and BV2 cell lines by inhibition of PI3K/AKT signaling and cyclin D1 expression and/or induced the expression of TNF-α and IL-6. Furthermore, bortezomib treatment resulted in dramatic degradation of IDH2 mutants, including R140G, R140Q, R140W, R172S and R172K, whereas it had little impact on the expression of WT and other mutants (R172M, R172W, R172G, R172C and R172P). In addition, targeting HSP90 minimally affected the expression of mutated IDH2 due to a lack of interaction between HSP90 and IDH2. The homology model further revealed that changes in conformation and IDH2 protein stability appeared to be associated with these point mutations. Taken together, our findings provide information important for understanding the molecular mechanisms of IDH2 mutations in tumors.

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications

IDH1/2 Mutations Target a Key Hallmark of Cancer by Deregulating Cellular Metabolism in Glioma

Analysis of Isocitrate Dehydrogenase-1/2 Gene Mutations in Gliomas.

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma

To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability

IDH gene mutation in glioma

IDH Mutations Associated Impact on Related Cancer Epidemiology and Subsequent Effect Toward HIF-1α

Metabolism of glioma and IDH1/IDH2 mutations

Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.

Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors

Idh1/Idh2 Mutations Define The Prognosis And Molecular Profiles Of Patients With Gliomas: A Meta-Analysis

Effects of cancer-associated point mutations on the structure, function, and stability of isocitrate dehydrogenase 2

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

Isocitrate Dehydrogenase (IDH)1/2 Mutations As Prognostic Markers in Patients with Glioblastomas

Comprehensive Exploration of Isocitrate Dehydrogenase (IDH) Mutations: Tumorigenesis, Drug Discovery, and Covalent Inhibitor Advances

Mechanisms Underlying The Biological Changes Induced By Isocitrate Dehydrogenase-1 Mutation In Glioma Cells